Why Endo Wants to Acquire Auxilium So Much
Endo International made an unsolicited buyout offer to Auxilium Pharmaceuticals, right after the latter announced that it had entered into an agreement to merge with QLT.
Endo International made an unsolicited buyout offer to Auxilium Pharmaceuticals, right after the latter announced that it had entered into an agreement to merge with QLT.
Avanir Pharmaceuticals posted amazing gains on Monday following the announcement of a successful Phase 1 trial, but is it now fully valued?
Shares of Rewalk Robotics surged again on Monday, following its initial public offering on Friday.
A new research report from UBS focuses on four top companies that are making great strides in treatments for patients -- and generating gigantic revenues.
Avanir Pharmaceuticals announced positive Phase 2 results for its drug candidate AVP-923, a potential new therapy for patients with Alzheimer’s disease.
NPS Pharmaceuticals traded lower on what sounded like good news. The problem is that headlines often do not reveal the true underlying story.
Health Care REIT has joined the waves of companies looking to raise capital after strong share price gains.
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest report.
ThinkstockVirobay, Inc. has filed with the Securities and Exchange Commission for an initial public offering. There were no terms given for the offering but the filing is for up to $50 million in common. The company…
ThinkstockNPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is up huge in regular trading on Wednesday, due to positive preliminary results of a clinical trial. The FDA has posted the briefing materials prior to the meeting for approval.…
Xenon Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.
While not flashy or super high-profile, these health care companies are expected to deliver solid earnings growth for the foreseeable future.
PRA Health Sciences has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.
A new report from the biotech team at Deutsche Bank fields questions from clients asking for specific stocks to buy for the rest of this year and 2015, and the analysts keep the answers…
SunTrust Robinson Humphrey opens up coverage of the biotech sector with four top biotech stocks to buy and one Neutral-rated stock.